

Canada Pharmaceutical Industry 2016

<https://marketpublishers.com/r/C993B05217CEN.html>

Date: February 2016

Pages: 160

Price: US\$ 850.00 (Single User License)

ID: C993B05217CEN

Abstracts

The Canadian pharmaceutical market is the eighth largest in the world, accounting for about two percent of the world market by sales. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The Canadian pharmaceutical industry is gradually becoming more favorable towards generic drugs rather than branded drugs.

Although the pharmaceutical industry claims to be a high-risk business, year after year drug companies enjoy higher profits than any other industry. The pharmaceutical industry is one of the most innovative and profitable industries in Canada. This industry is composed of brand-name drug companies (which include biopharmaceutical companies) and generic drug companies. Both segments produce prescription and non-prescription drugs

Aruvian Research's report – Canada Pharmaceutical Industry – explores the Canadian Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the TRIPS agreement and the effect of the agreement on the Canadian pharmaceutical industry, growth trends in the industry, competition in the industry, etc.

The report also analyzes the Canadian pharmaceutical industry through two frameworks – a SWOT analysis and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Canadian Pharmaceutical Industry, and the role of the government in the industry.

Complete with a comprehensive section on the clinical trials, market investment opportunities going on in the Canadian pharmaceutical industry, Aruvian's latest research is a collection of all you need to know about Canada's Pharmaceutical Industry.

Contents

A. EXECUTIVE SUMMARY

B. INTRODUCTION TO THE INDUSTRY

- B.1 Industry Definition
- B.2 Canada's Pharmaceutical Sector – SWOT Framework Analysis
 - B.2.1 Strengths to Build On
 - B.2.2 Weaknesses to Overcome
 - B.2.3 Opportunities to Exploit
 - B.2.4 Threats to Overcome
- B.3 Industry Overview
- B.4 Size & Structure of the Industry
- B.5 Industry Growth by Value Analysis
- B.6 Market Segments
- B.7 Canadian Drug Sales
- B.8 Competition in the Industry
- B.9 Market Share Analysis
- B.10 Major Growth Factors
- B.11 Canada's Pharmaceutical Industry's Cost Advantage
- B.12 Clinical Trials
- B.13 Market Access

C. OTC PHARMACEUTICALS IN CANADA

- C.1 Industry Definition
- C.2 Industry Overview
- C.3 Industry Growth by Value Analysis
- C.4 Market Segments
- C.5 Competition in the Industry
- C.6 Market Share
- C.7 Distribution Channels
- C.8 Industry Forecast

D. GENERICS MARKET IN CANADA

- D.1 Industry Definition
- D.2 Industry Overview

- D.3 Industry Growth by Value Analysis
- D.4 Industry Growth by Volume Analysis
- D.5 Geographical Segmentation
- D.6 Competition in the Industry
- D.7 Industry Forecast

E. REGULATORY DEVELOPMENTS & TRENDS IN THE INDUSTRY

F. PORTER'S FIVE FORCES STRATEGY ANALYSIS OF CANADA'S PHARMACEUTICAL INDUSTRY

- F.1 Bargaining Power of Buyers
- F.2 Bargaining Power of Suppliers
- F.3 Competitive Rivalry in the Industry
- F.4 Threat of New Entrants
- F.5 Threat of Substitutes
- F.6 Conclusion

G. PRICING AND REIMBURSEMENT SYSTEM IN THE INDUSTRY

H. RE-IMPORT POLICIES FOR DRUGS

I. PHARMACEUTICAL R&D IN CANADA

J. TRIPS & CANADA

- J.1 Doha Declaration
- J.2 Canadian Legislation
- J.3 Humanitarian Contributions of Canadian Companies

K. INDUSTRY FORECAST

L. MAJOR INDUSTRY PLAYERS

- L.1 Allergan Plc
 - L.1.1 Corporate Profile
 - L.1.2 Business Segment Analysis
 - L.1.3 Financial Analysis
 - L.1.4 SWOT Analysis

- L.2 AstraZeneca PLC
 - L.2.1 Corporate Profile
 - L.2.2 Business Segment Analysis
 - L.2.3 Financial Analysis
 - L.2.4 SWOT Analysis
- L.3 GlaxoSmithKline Plc
 - L.3.1 Corporate Profile
 - L.3.2 Business Segment Analysis
 - L.3.3 Financial Analysis
 - L.3.4 SWOT Analysis
- L.4 Johnson & Johnson
 - L.4.1 Corporate Profile
 - L.4.2 Business Segment Analysis
 - L.4.3 Financial Analysis
 - L.4.4 SWOT Analysis
- L.5 Mylan N.V.
 - L.5.1 Corporate Profile
 - L.5.2 Business Segment Analysis
 - L.5.3 Financial Analysis
 - L.5.4 SWOT Analysis
- L.6 Pfizer Inc.
 - L.6.1 Corporate Profile
 - L.6.2 Business Segment Analysis
 - L.6.3 Financial Analysis
 - L.6.4 SWOT Analysis
- L.7 Sanofi SA
 - L.7.1 Corporate Profile
 - L.7.2 Business Segment Analysis
 - L.7.3 Financial Analysis
 - L.7.4 SWOT Analysis
- L.8 Teva Pharmaceutical Industries Limited
 - L.8.1 Corporate Profile
 - L.8.2 Business Segment Analysis
 - L.8.3 Financial Analysis
 - L.8.4 SWOT Analysis
- L.9 Apotex Holdings
- L.10 Sandoz International GmbH

M. GLOSSARY OF TERMS

List Of Figures

LIST OF FIGURES

Figure 1: Average Profit Margins for Selected Industries (2009-2014)

Figure 2: Distribution of Pharmaceutical R&D Expenditures by Geographic Areas - 2014

Figure 3: Growth in the Canadian Pharmaceuticals Market by Value (in USD Billion), 2010-2014

Figure 4: Share of the Canadian Pharmaceutical Industry in the Americas (%), 2014

Figure 5: Market Share Analysis of the Canadian Pharmaceutical Industry (%), 2014

Figure 6: Growth of the Canadian OTC Pharmaceutical Market in Value Terms (in USD Million), 2010-2014

Figure 7: Canadian OTC Pharma Market Segmentation (%), 2014

Figure 8: Share of Canada's OTC Market in the Americas (%), 2014

Figure 9: Market Share of the Canadian OTC Pharmaceutical Industry (%), 2014

Figure 10: Leading Distribution Channels in Canada's OTC Pharmaceutical Industry (%), 2014

Figure 11: Forecast of the Canadian OTC Pharmaceutical Industry (in USD Million), 2014-2019

Figure 12: Growth of the Canadian Generics Industry by Value (in USD Million), 2010-2014

Figure 13: Growth of the Canadian Generics Industry by Volumes (in Percentage of Total Pharma Industry Volume), 2010-2014

Figure 14: Share of Canada in the Americas Generics Industry (%), 2014

Figure 15: Forecast of the Canadian Generics Industry (in USD Million), 2014-2019

Figure 16: Volume Forecast of the Canadian Generics Industry (in Percentage of Total Pharmaceutical Industry Volume), 2014-2019

Figure 17: Porter's Five Forces Analysis of the Canadian Pharmaceutical Industry

Figure 18: Bargaining Power of Buyers in the Canadian Pharmaceutical Industry

Figure 19: Bargaining Power of Suppliers in the Canadian Pharmaceutical Industry

Figure 20: Competitive Rivalry in the Canadian Pharmaceutical Industry

Figure 21: Threat of New Entrants to the Canadian Pharmaceutical Industry

Figure 22: Threat of Substitutes to the Canadian Pharmaceutical Industry

Figure 23: Forecast of the Canadian Pharmaceutical Industry (in USD Billion), 2014-2019

List Of Tables

LIST OF TABLES

Table 1: Growth in the Canadian Pharmaceuticals Market by Value (in USD Billion), 2010-2014

Table 2: Canada Pharmaceuticals Market Segmentation % Share, by Value, 2014

Table 3: Share of the Canadian Pharmaceutical Industry in the Americas (in USD Billion & %), 2014

Table 4: Health Expenditure Indicators

Table 5: International Cost Comparison of the Pharmaceutical Industry (US = 100)

Table 6: Growth of the Canadian OTC Pharmaceutical Market in Value Terms (in USD Million), 2010-2014

Table 7: Canadian OTC Pharma Market Segmentation (in USD Million & %), 2014

Table 8: Share of Canada's OTC Market in the Americas (in USD Million & %), 2014

Table 9: Forecast of the Canadian OTC Pharmaceutical Industry (in USD Million), 2014-2019

Table 10: Growth of the Canadian Generics Industry by Value (in USD Million), 2010-2014

Table 11: Growth of the Canadian Generics Industry by Volumes (in Percentage of Total Pharma Industry Volume), 2010-2014

Table 12: Share of Canada in the Americas Generics Industry (in USD Million & %), 2014

Table 13: Forecast of the Canadian Generics Industry (in USD Million), 2014-2019

Table 14: Volume Forecast of the Canadian Generics Industry (in Percentage of Total Pharmaceutical Industry Volume), 2014-2019

Table 15: Innovators' Reasons for Cooperating

Table 16: Forecast of the Canadian Pharmaceutical Industry (in USD Billion), 2014-2019

Table 17: Key Financials of Allergan Plc (in USD Million), 2014-2015

Table 18: Key Financials of AstraZeneca (in USD Million), 2014-2015

Table 19: Key Financials of GSK (in USD Million), 2014-2015

Table 20: Key Financials of Johnson & Johnson (in USD Million), 2014-2015

Table 21: Key Financials of Mylan N.V. (in USD Million), 2014-2015

Table 22: Key Financials of Pfizer Inc. (in USD Million), 2014-2015

Table 23: Key Financials of Sanofi SA (in USD Million), 2014-2015

Table 24: Key Financials of Teva Pharmaceutical Industries (in USD Million), 2014-2015

I would like to order

Product name: Canada Pharmaceutical Industry 2016

Product link: <https://marketpublishers.com/r/C993B05217CEN.html>

Price: US\$ 850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C993B05217CEN.html>